A Comparison Between Clobetasol Propionate 0.05% (Clobex®) Spray and Clobetasol Propionate 0.05% (Olux®) Foam
Phase 4
Completed
- Conditions
- Psoriasis
- Interventions
- Registration Number
- NCT00436540
- Lead Sponsor
- Galderma R&D
- Brief Summary
The primary objective of this study is to evaluate the efficacy and safety of clobetasol propionate 0.05% (Clobex®) spray compared to clobetasol propionate 0.05% (Olux®) foam.
- Detailed Description
Same as above.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
- Subjects must have a clinical diagnosis of moderate to severe plaque psoriasis, defined as 3%-20% of the body surface area involved
Exclusion Criteria
- Subjects who have surface area involvement too large that would require more than 50 grams per week of Clobex® spray or more than 50 grams per week of Olux® foam
- Subjects whose psoriasis involves the scalp, face or groin
- Subjects with non-plaque psoriasis or other related diseases not classified as plaque psoriasis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 1 Clobetasol Propionate 0.05% Spray clobetasol propionate (Clobex®) spray 2 Clobetasol Propionate 0.05% Foam clobetasol propionate (Olux®) foam
- Primary Outcome Measures
Name Time Method Efficacy - Body Surface Area, Investigator Global Severity 6 weeks
- Secondary Outcome Measures
Name Time Method Safety - Tolerability assessments, adverse events 6 weeks
Trial Locations
- Locations (2)
Solano Clinical Research
🇺🇸Vallejo, California, United States
Central Dermatology, PC
🇺🇸Saint Louis, Missouri, United States
Solano Clinical Research🇺🇸Vallejo, California, United States